Neurotez Inc.'s original offering opened on January 2, 2018 and was completed on February 26, 2018. Except for the Updates section which may contain more recent information, the information on this page was accurate as of February 26, 2018.

Neurotez, Inc.

Neurotez Inc. is developing a drug to treat Leptin deficiency in Alzheimer’s patients.

Best buy price


Best sell price




Range of prices

$0.50 — $2

Full bid-ask spread

From the CEO

“I have personal experience on how devastating a brain disorder that changes your behavior and personality can be. My mother, who died in 2014, suffered from Alzheimer’s. My personal commitment is to develop a cure for Alzheimer’s disease, no matter what this may cost. There is no plan B.”

- Nikolaos Tezapsidis

Neurotez demo


Alzheimer’s disease affects more than 5 million Americans and 40 million patients worldwide.

Current medications provide limited relief. Many of our competitors are focusing on removing either Abeta or tau deposits from the brain where they form plaques and tangles. None of these efforts have generated any effective drug for the last 18 years since the first anti-Abeta trial started.

The idea that Abeta and plaque do not cause Alzheimer’s is gaining momentum in the research community. We were determined to look for a different solution prior to the formation of the plaques.

Industry Snapshot

“Alzheimer’s disease market will more than double to $11.3 Billion by 2021.” GBI Research


Our novel approach focuses on Leptin, a naturally occurring human hormone associated with various metabolic effects, has a large number of receptors in memory centers of the brain.

Hippocampus (in red) responsible for memory formation, cognition and executive function is severely affected by the disease. This region is rich in Leptin receptors.

This protein is often present at decreased levels in patients suffering from Alzheimer’s disease, and cognitive deterioration in AD patients correlates strongly with a decline in circulating Leptin levels.

We are developing Memtin™ to treat Leptin deficiency in Alzheimer’s patients. This Leptin product will act as a novel hormone replacement therapy for Alzheimer’s disease (AD) and/or as a preventative for those who are at risk.




Operating Team

An impressive group of exceptional individuals with deep experience and success in their respective fields in Academia (1000s of publications in Alzheimer’s) and Pharmaceutical Industry have been working together for a number of years to achieve our mission.

Nikolaos Tezapsidis
President and CEO
  • PhD in Biochemistry at the University of Sussex, UK
  • 18+ years of biomedical research
  • Two awards from the Alzheimer’s Association
Wes Ashford
Chief Medical Officer
  • MD and PhD in Neuroscience from UCLA
  • 100+ publications on Alzheimer’s disease
  • Senior Research Scientist at the Stanford/VA Aging Clinical Research Center and Alzheimer’s Center
George Perry
Chief Science Officer
  • PhD in Marine Biology from Scripps Institution of Oceanography
  • 1,000+ publications on Alzheimer's disease
  • Semmes Foundation Endowed Chair in Neurobiology at the University of Texas at San Antonio
Hamish McArthur
Chief Manufacturing Officer
  • PhD in Microbial Biochemistry at University of Cambridge
  • 33 years of drug development experience at Pfizer
  • 50+ publications and patents
Jukka Karjalainen
  • 25+ years of pharma experience in US, Canada, and Europe
  • Authored 55 original publications in top-rated international medical journals
  • Member of International Science Advisory Board
Jane Johnston
VP Operations
  • PhD in Biochemistry from Imperial College
  • 18+ years of research experience in neural repair and cellular imaging
  • Principal Investigator for the University of Medicine and Dentistry of New Jersey and Albert Einstein College of Medicine
Michael Hoy
Consultant in Regulatory Affairs
  • MS in Clinical Pharmacology from Thomas Jefferson University
  • Extensive experience in early phase clinical development, regulatory affairs, and life-cycle management
  • Worked at Bristol-Myers Squibb, Wyeth, and Johnson & Johnson
Bob Oliver
  • MBA in Marketing from the Haub School of Business at Saint Joseph’s University
  • President and CEO of Otsuka America Pharmaceutical, Inc.
  • VP and Global Business Manager for Oncology at Wyeth
James Harris
acting CFO
  • MBA in Finance from Long Island University
  • CEO of Healthcare Economics LLC
  • VP at Dragon Pharmaceuticals, Inc.
Thomas J. Humphries
  • 36 years of experience in Pharma and Biotech
  • 225+ papers published
  • Retired as a Colonel after 26 years in the Navy and Airforce

Memtin™ Development Timeline

Previous Funding

Total = $4.5M

  • National Institutes of Health
  • IRS Qualifying Therapeutic Discovery Project grant
  • New Jersey Commission of Science and Technology

Pitch Deck

arrows remove Created with Sketch.

More Info

Use of Proceeds

To be used for General Corporate purposes including legal, accounting, marketing, and salary expenses.

If the offering's maximum amount of $107,000 is raised:

UseValue% of Proceeds
Compensation for Directors, Officers, and Promoters$5,0004.7%
Debt Repayment$10,0009.3%
Intermediary fees$5,2434.9%


This is an offering of Common Stock, under registration exemption 4(a)(6), in Neurotez Inc.. This offering must raise at least $10,000 by February 26, 2018 at 4:00pm ET. If this offering doesn’t reach its target, then your money will be refunded. Neurotez Inc. may issue additional securities to raise up to $107,000, the offering’s maximum.

$10,000 minimum
$95,209 raised

If the offering is successful at raising the maximum amount, then the company’s implied valuation after the offering (sometimes called its post-money valuation) will be:

$1 per share
$11,129,345implied valuation

Pitch Deck


These financial statements have been reviewed by an independent Certified Public Accountant.

SEC Filings

The Offering Statement is a formal description of the company and this transaction. It’s filed with the SEC to comply with the requirements of exemption 4(a)(6) of the Securities Act of 1933.

We’re also required to share links to each of the SEC filings related to this offering with investors.

Understand the Risks

Be sure to understand the risks of this type of investment. No regulatory body (not the SEC, not any state regulator) has passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials or information posted herein. That’s typical for Regulation CF offerings like this one.

Neither Netcapital nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.

The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

More Info


  • Jun 23, 2021
    Thank you to all Neurotez investors and...

    Thank you to all Neurotez investors and Netcapital team for making this a successful campaign. We are much encouraged and will continue our efforts to develop our promising drug for Alzheimer’s, much needed.

  • May 19, 2021
    Neurotez participating at the Clinical Trials...

    Neurotez participating at the Clinical Trials Nexus Series

    Read More
  • Feb 23, 2021
    #Neurotez envisages opening a French European...

    #Neurotez envisages opening a French European branch in the near future to facilitate the clinical development of it’s assets, including #Memtin. For this, Jerome Delahaye from I/eCreactiv is acting as strategic consultant for Neurotez in “exploring opportunities to partner with French local authorities, European companies and institutes in the areas of financing, R&D, manufacturing …

  • Feb 23, 2021
    Neurotez has been nominated as one of the most...

    Neurotez has been nominated as one of the most innovative companies at the 2021 BIO Digital under the Technologies of Tomorrow category. How to vote for us: (voting begins today, Feb 23)… Vote for “Neurotez” to be recognized as the Buzz of BIO in the Technologies of Tomorrow Category! Cast your vote by February 25 to help us win! Vote Here: @BIOConvention Voting will run from February 23 at 9:00 am ET and close on February 25 at 5:00 pm ET, so spread the word about your company’s participation!

    Please vote for us
  • Feb 26, 2018
    Primary offering finalized, selling 95,209 shares
    Sold 95,209 shares at $1 for a total of $95,209

Ask a Question

Proofread your comment before submitting: once it's posted, you can’t edit or delete it. For the fastest help with the web site, email instead of commenting.

Looking to raise capital?
We can help turn your friends, family and customers into investors.

Learn more

Interested in more investment opportunities?
Browse all offerings currently available.

See more